Ultrahigh Field (UHF) human MRI has a history of more than 30 years of technology development enabling the introduction of the first clinical 7T MRI, which was FDA approved in 2017. Currently approved MSK applications are limited to the knee, where improved SNR with higher resolution and contrast can make a clinical difference. However, to develop UHF MRI for a wide range of clinical MSK applications to its full potential, introduction of Parallel Transmit Technology (PTx) is needed to overcome current limitations. Beyond 7T there are exciting possibilities for human MSK-research at 10.5T, such as Na+ MRI for cartilage.